Latest Conference

Elizabeth Hirsch, PharmD, and Elizabeth Smith, PharmD candidate, discuss fosfomycin susceptibility testing.

Minh-Hong Nguyen, MD, discusses rezafungin as a potential treatment option for intra-abdominal candidiasis.

Steven Tong, PhD, discusses the benefit of investigator-initiated studies.

László Majoros, MD, PhD, discusses how nearly all invasive fungal infections are being treated with echinocandins.

Initiating and adhering to ART is a difficult task for a significant number of people living with HIV. A new study shows that making a concerted effort to find and encourage this population to get the care they need is not an impossible dream.

Tristan Ferry, MD, PhD, discusses bacteriophage therapy as an alternative treatment for certain patients.

Marin Kollef, MD, discusses what makes the 3-gram dose regimen of ceftolozane/tazobactam unique.

The percentage of participants who achieved HIV-1 RNA< 50 copies/mL in the 0.25 mg, 0.75 mg, 2.25 mg MK-8591 dose groups was 89.7%, 90.0%, and 77.4%, respectively, at week 48.

At week 48, 83.8% of participants in the TAF/FTC/DTG arm had HIV RNA < 50 copies/mL, 84.9% for TDF/FTC/DTG and 78.6% for TDF/FTC/EFV.

The final results of HOPE, a phase 3 open-label extension trial, show high uptake and lower-than-anticipated HIV-1 incidence.

New results indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA > 50 copies per mL at week 48.

Glenn Tillotson, PhD, discusses possible avenues for future research on gram-negative skin infections and inappropriate empiric therapy.

With 1329.6 person-years of PrEP use accumulated, early continuation was achieved by 79.8% of participants.

The phase 2a study compares a bivalent combination of Clade C and Mosaic gp140 with a single-valent Clade C gp140.

Providers who received the intervention materials had higher satisfaction and confidence in prescribing chronic opioid therapy than their colleagues who did not.

Matthew Girgis, PharmD, PGY-2, discusses why it's advantageous to decrease patient exposure to vancomycin.

We asked providers in the field why they pursued a career in infectious disease.

Two phase 3 studies presented at IAS 2019 evaluated a switch to B/F/TAF among individuals virologically suppressed on other HIV treatment regimens.

A handful of new studies weighing the risks and benefits of ART regimens containing dolutegravir have triggered new recommendations from the WHO.

The team assessed program engagement, medication refills, and self-reported 3-day adherence over 72 weeks, among the individuals who initiated PrEP.

The difference between NTD prevalence with dolutegravir and non-dolutegravir antiretrovirals from conception was small, but significant at 0.20% difference (95%CI 0.01%, 0.59%).

As little as 10 minutes of ocean swimming can replace the skin microbiome, and bacteria can persist on skin for 24 hours after swimming.

Cases of C auris have been reported in 12 states. Investigators believe they’ve found a new way to attack the fungus using combinations of antifungal and antibacterial medications.

Bacteriophages found in kitchen sponges may hold promise for the treatment of antimicrobial-resistant bacterial infections.

The global emergence of antimicrobial resistance among gram-negative species is a major public health concern.

A symposium at ASM Microbe 2019 considered some specific examples of how bacteriophage shape the microbiome and also zoomed out for a higher-altitude view of the microbiome.

A look at the latest developments in drugs intended to quell gram-positive pathogens, including Clostridioides difficile and non-tuberculosis mycobacterial infections, as presented at ASM Microbe 2019.

Glenn Tillotson, PhD, explains how inappropriate empiric therapy can drive poor outcomes.